Ophthalmology Approved Deal Benchmarks — Europe (2026)
Median upfront of $882M with total deal values reaching $2.3B in Europe territory.
Median Upfront
$882M
Total Deal Value
$2.0B
Royalty Range
11.8%–20%
Territory Multiplier
0.25x
Understanding Ophthalmology Deal Benchmarks at Approved
Approved Ophthalmology licensing deals in Europe territory command a median upfront payment of $882M, with values ranging from $654M at the low end to $1.0B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the ophthalmology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.7B to $2.3B, with a median of $2.0B. Royalty rates for ophthalmology assets at this stage typically fall between 11.8% and 20% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $654M | $882M | $1.0B |
| Total Deal Value | $1.7B | $2.0B | $2.3B |
| Royalty Rate | 11.8% | — | 20% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Aldeyra Therapeutics | Partner | $50M | $350M | licensing |
| 2022 | Tarsus Pharmaceuticals | Samsung | $30M | $210M | licensing |
See All Comparable Deals
View 2 comparable Ophthalmology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Ophthalmology deals in Europe territory?
How does Europe territory affect Ophthalmology deal value?
What royalty rates are typical for Approved Ophthalmology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$15M upfront
Ophthalmology · Preclinical · Europe
$39M upfront
Ophthalmology · Phase 1 · Europe
$124M upfront
Ophthalmology · Phase 2 · Europe
$340M upfront
Ophthalmology · Phase 3 · Europe
$519M upfront
Oncology · Approved · Europe
$369M upfront
Neurology/CNS · Approved · Europe
$854M upfront
Immunology · Approved · Europe
$871M upfront
Metabolic/Obesity · Approved · Europe
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Ophthalmology Approved Deal Benchmarks — Europe (2026). Retrieved from https://solidus.ambrosiaventures.co/data/ophthalmology-approved-deals-europe
<a href="https://solidus.ambrosiaventures.co/data/ophthalmology-approved-deals-europe">Ophthalmology Approved Deal Benchmarks — Europe (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=ophthalmology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.